JY028 Single Vitreous Injection in a Phase 1 Clinical Trial in nAMD Patients

Not Applicable

• Conditions: Macular Degeneration
• Interventions: Drug: Experimental

• Registration Number: NCT03725566
• Lead Sponsor: Beijing Tongren Hospital

Brief Summary

Phase I clinical trial on safety, tolerance, pharmacokinetics (PK) and pharmacodynamics of recombinant human anti-VEGF monoclonal antibody injection in patients with neovascular (wet) age-related macular degeneration

Detailed Description

Test drug:Recombinant humanized anti VEGF monoclonal antibody injection; Research Phase:Phase I; Subjects:Subjects with neovascular (wet) age-related macular degeneration; Number of Subjects:24; Trial design:Single center, non randomized, open, single arm, single dose, dose escalation; Research objective:to rearch the safety and tolerance of JY028 injection;to rearch PK of JY028 injection;to observe the efficacy of JY028 in the treatment of nAMD;to rearch the relationship between plasma VEGF concentration and JY028 concentration. to rearch immunogenicity of JY028;

Study Timeline

• Study Start: 2018-05-22
• Status Verified: 2018-09
• Study First Submitted: 2018-09-20
• Study First Submitted QC: 2018-10-30
• Last Update Submitted: 2018-10-30
• Study First Posted: 2018-10-31
• Last Update Posted: 2018-10-31
• Primary Completion: 2020-05-01
• Study Completion: 2020-05-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. The patient volunteered to participate and signed the informed consent 2. No more than 50 years of age and less than 75 years of age, male or female 3. Diagnosed as nAMD 4. The optimal corrected visual acuity of the target eye ETDRS should be no more than 50 letters, and the optimal corrected visual acuity of the opposite eye should be no more than 34 letters 5. The target eye pressure is no more than 25mmHg, which can be controlled by drugs 6. A normal coagulation function: the platelet count is 100 x 10 ^ 9-300x 10^10 / L, thrombin time, prothrombin time within the normal range.

Exclusion Criteria

1. Choroid polypoid angiopathy (PCV)
2. There are other obvious eye diseases/conditions (such as diabetic retinopathy, cataract, abnormal eyelid, uncontrolled glaucoma, eye active inflammation, etc.)
3. CNV caused by other causes other than nAMD, such as diabetic retinopathy, vascular stripe disease, ocular histoplasmosis, case myopia, trauma, etc
4. The target eye has received any intraocular surgery or laser therapy within 3 months prior to enrollment
5. Any eye treated with antiangiogenic drugs within 3 months prior to baseline visit
6. Patients with active eye infections, such as conjunctivitis, keratitis, sclerotic, blepharitis, endophthalmitis or uveitis
7. Persons with a history of myocardial infarction and/or cerebral infarction or other active or acute cardiovascular diseases
8. HIV antibody/hiv-p24 antigen, any of the positive subjects in the treponema pallidum antibody
9. Active HBsAg carriers (conditions must be met: HBsAg positive, HBV DNA positive, ALT higher than normal upper limit)
10. Patients with HCV (the following conditions must be met: lgM positive anti-hcv antibody, ALT higher than the upper limit of normal value)
11. Fluorescein sodium allergy
12. Allergy to anti-vegf monoclonal antibodies or humanized monoclonal antibodies
13. Patients who participated in other clinical trials within 3 months
14. Patients who took NSAIDs and aspirin or other anticoagulant or platelet drugs within 1 month before enrollment
15. An unhealed wound, ulcer, fracture, or other related medical condition
16. Patients with uncontrollable hypertension, with systolic blood pressure of > 140mmHg and diastolic blood pressure of > 90mmHg
17. Patients with uncontrollable clinical diseases or problems (such as serious mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant tumors)
18. Pregnant and lactating women and those who cannot take contraceptive measures
19. According to the researcher, it is not suitable for the candidate -

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Experimental	Experimental	Recombinant humanized anti-VEGF monoclonal antibody injection 0.625mg/1.25mg/2.0mg/2.5mg by intravitreous injection,day 1 in the first month;

Primary Outcome Measures

Name	Time	Method
JY028 related incidence of ocular and systemic adverse events and serious adverse events	13 weeks	JY028 related incidence of ocular and systemic adverse events and serious adverse events

Secondary Outcome Measures

Name	Time	Method
BCVA	13 weeks	The best corrected visual acuity change
AUC0-t、AUCinf	13 weeks	The area under the plasma concentration time curves
Tmax	13 weeks	Peak time of blood drug concentration
Cmax	13 weeks	Maximum blood drug concentration

Trial Locations

Locations (1)

Beijing Tongren Hospital; 🇨🇳 Beijing, Beijing, China